CN103857672B - 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 - Google Patents

用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 Download PDF

Info

Publication number
CN103857672B
CN103857672B CN201280049302.7A CN201280049302A CN103857672B CN 103857672 B CN103857672 B CN 103857672B CN 201280049302 A CN201280049302 A CN 201280049302A CN 103857672 B CN103857672 B CN 103857672B
Authority
CN
China
Prior art keywords
compound
formula
mixture
dichloro
fluoroanilino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280049302.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103857672A (zh
Inventor
房极赞
文荣沪
张永佶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103857672(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Priority to CN201811593540.XA priority Critical patent/CN110003174A/zh
Publication of CN103857672A publication Critical patent/CN103857672A/zh
Application granted granted Critical
Publication of CN103857672B publication Critical patent/CN103857672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280049302.7A 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 Active CN103857672B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811593540.XA CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110101422A KR101272613B1 (ko) 2011-10-05 2011-10-05 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
KR10-2011-0101422 2011-10-05
PCT/KR2012/008077 WO2013051883A2 (en) 2011-10-05 2012-10-05 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811593540.XA Division CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Publications (2)

Publication Number Publication Date
CN103857672A CN103857672A (zh) 2014-06-11
CN103857672B true CN103857672B (zh) 2018-11-30

Family

ID=48044309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280049302.7A Active CN103857672B (zh) 2011-10-05 2012-10-05 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
CN201811593540.XA Pending CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811593540.XA Pending CN110003174A (zh) 2011-10-05 2012-10-05 一种盐酸盐化合物的制备方法

Country Status (23)

Country Link
US (1) US8859767B2 (enExample)
EP (2) EP2763981B1 (enExample)
JP (1) JP5805880B2 (enExample)
KR (1) KR101272613B1 (enExample)
CN (2) CN103857672B (enExample)
AU (1) AU2012319291B2 (enExample)
BR (1) BR112014007718B1 (enExample)
CA (1) CA2850055C (enExample)
CY (1) CY1122758T1 (enExample)
DK (1) DK2763981T3 (enExample)
ES (1) ES2775197T3 (enExample)
HR (1) HRP20200426T1 (enExample)
HU (1) HUE048798T2 (enExample)
IL (3) IL231911B (enExample)
IN (1) IN2014DN03447A (enExample)
LT (1) LT2763981T (enExample)
MX (1) MX348815B (enExample)
PL (1) PL2763981T3 (enExample)
PT (1) PT2763981T (enExample)
RS (1) RS60118B1 (enExample)
RU (1) RU2563630C1 (enExample)
SI (1) SI2763981T1 (enExample)
WO (1) WO2013051883A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
HK1244278B (zh) 2015-03-20 2020-04-17 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
EP3849964A4 (en) * 2018-09-14 2022-06-08 Hanmi Pharmaceutical Co., Ltd. CRYSTALLINE FORMS OF A QUINAZOLE COMPOUND AND ITS HYDROCHLORIDE SALTS
KR101950942B1 (ko) * 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
US20220064145A1 (en) * 2020-08-28 2022-03-03 Hanmi Science Co., Ltd. Synthesis of poziotinib derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
ATE353888T1 (de) * 2003-09-19 2007-03-15 Astrazeneca Ab Chinazolinderivate
AU2006326157A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
MX2011011177A (es) * 2009-04-23 2011-11-18 Astrazeneca Ab Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030765A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives as antiproliferative agents
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物

Also Published As

Publication number Publication date
CA2850055C (en) 2016-05-17
RU2563630C1 (ru) 2015-09-20
IL259694A (en) 2018-07-31
LT2763981T (lt) 2020-05-25
WO2013051883A3 (en) 2013-06-06
HRP20200426T1 (hr) 2020-09-04
BR112014007718A2 (pt) 2017-04-25
PT2763981T (pt) 2020-03-25
CY1122758T1 (el) 2021-03-12
KR20130037079A (ko) 2013-04-15
BR112014007718B1 (pt) 2022-02-22
SI2763981T1 (sl) 2020-07-31
AU2012319291A1 (en) 2014-05-22
DK2763981T3 (da) 2020-03-16
RS60118B1 (sr) 2020-05-29
MX2014003959A (es) 2014-05-14
AU2012319291B2 (en) 2016-03-31
US8859767B2 (en) 2014-10-14
EP2763981A4 (en) 2015-02-25
HUE048798T2 (hu) 2020-08-28
IL231911A0 (en) 2014-05-28
CA2850055E (en) 2013-04-11
CN110003174A (zh) 2019-07-12
WO2013051883A2 (en) 2013-04-11
EP2763981A2 (en) 2014-08-13
MX348815B (es) 2017-06-30
ES2775197T3 (es) 2020-07-24
EP3611172A1 (en) 2020-02-19
IL291738A (en) 2022-05-01
CA2850055A1 (en) 2013-04-11
US20140275534A1 (en) 2014-09-18
JP2014528444A (ja) 2014-10-27
CN103857672A (zh) 2014-06-11
KR101272613B1 (ko) 2013-06-10
JP5805880B2 (ja) 2015-11-10
PL2763981T3 (pl) 2020-08-10
IN2014DN03447A (enExample) 2015-06-26
IL259694B (en) 2022-04-01
IL231911B (en) 2018-06-28
EP2763981B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
CN103857672B (zh) 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
JP7051929B2 (ja) １－（４－（４－（３，４－ジクロロ－２－フルオロフェニルアミノ）－７－メトキシキナゾリン－６－イルオキシ）ピペリジン－１－イル）プロパ－２－エン－１－オンの製造方法
WO2017186140A1 (zh) 一种制备酪氨酸激酶抑制剂及其衍生物的方法
HK1196132B (zh) 用於制备1-(4-(4-(3，4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物
HK40010388A (en) Preparation method for hydrochloride compound
HK1196132A (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein
KR101950942B1 (ko) 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN107629014A (zh) 5‑甲基‑4h‑1,2,4‑三唑‑3‑乙酸的合成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1196132

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant